Related Experiment Video
Updated: May 7, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
14.8K
The Association Between Statin Drugs and Rhabdomyolysis: An Analysis of FDA Adverse Event Reporting System (FAERS)
Robert Morris1, Kun Bu2, Weiru Han2
1Department of Pharmaceutical Science, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33613, USA.
Genes
|March 28, 2025
Summary
Simvastatin significantly increases the risk of rhabdomyolysis, a dangerous muscle breakdown, compared to other statins. Men face a higher risk, and certain drug interactions may exacerbate this adverse event.
Area of Science:
- Pharmacovigilance and Pharmacoepidemiology
- Molecular Biology and Genetics
- Cardiovascular Pharmacology
Background:
- Statins are widely prescribed for hypercholesterolemia, but rhabdomyolysis is a serious adverse event.
- Understanding statin-specific risks is crucial for patient safety.
Purpose of the Study:
- To compare the risk of rhabdomyolysis associated with different statin drugs.
- To investigate potential drug-drug interactions and genetic factors contributing to statin-induced rhabdomyolysis.
Main Methods:
- Disproportionality analysis of FDA Adverse Event Reporting System (FAERS) data, comparing simvastatin to other statins.
- Association rule mining to identify co-occurring adverse events and drug-drug interactions (DDIs).
- Exploration of public transcriptomic data to identify genetic underpinnings of rhabdomyolysis risk.
Main Results:
- Simvastatin showed a >2-fold increased likelihood of rhabdomyolysis compared to other statins.
- Men had a higher risk of rhabdomyolysis than women; pravastatin and atorvastatin also showed elevated risks.
- Potential DDIs with furosemide, allopurinol, clopidogrel, and pantoprazole were identified, alongside nine myopathic genes.
Conclusions:
- Simvastatin is associated with the highest risk of rhabdomyolysis among statins.
- Male sex and specific DDIs contribute to increased rhabdomyolysis risk.
- Genetic factors, including nine identified myopathic genes, may play a role in statin-induced rhabdomyolysis.
Keywords:
DDIFAERSRNA-seqassociation rulesdrug interactionskidney injurymuscle diseasepharmacovigilancerhabdomyolysisstatinsMore Related Videos
Related Concept Videos
01:19Pharmacovigilance
2.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
2.0K
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
01:29Therapeutic Drug Monitoring: Affecting Factors
438
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
438
01:29Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
01:24Drug Toxicity: Risk factors
250
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
250
01:30Drug toxicity: Drug–Drug Interaction
437
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
437